Jagsonpal Pharmaceuticals Limited
Jagsonpal Pharmaceuticals Limited engages in the manufacturing, selling, and trading of pharmaceutical products and active pharmaceutical ingredients in India and internationally. It offers pharmaceutical formulations and products in the areas of gynaecology, orthopaedics, dermatology, and paediatrics. The company provides drugs in the form of tablets, softgels, injections, capsules, and syrups. … Read more
Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) - Total Liabilities
Latest total liabilities as of September 2025: ₹461.88 Million INR
Based on the latest financial reports, Jagsonpal Pharmaceuticals Limited (JAGSNPHARM) has total liabilities worth ₹461.88 Million INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Jagsonpal Pharmaceuticals Limited - Total Liabilities Trend (2006–2025)
This chart illustrates how Jagsonpal Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Jagsonpal Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Jagsonpal Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Artiva Biotherapeutics, Inc. Common Stock
NASDAQ:ARTV
|
USA | $19.64 Million |
|
Tristar Gold
OTCQB:TSGZF
|
USA | $2.60 Million |
|
Jaanh CosmeticsInc.
KQ:219550
|
Korea | ₩17.22 Billion |
|
Ray Co. Ltd
KQ:228670
|
Korea | ₩122.77 Billion |
|
Prostemics Co. Ltd
KQ:203690
|
Korea | ₩33.62 Billion |
|
CHA Vaccine Institute Co. Ltd.
KQ:261780
|
Korea | ₩22.26 Billion |
|
Intchains Group Limited American Depositary Shares
NASDAQ:ICG
|
USA | $40.13 Million |
Liability Composition Analysis (2006–2025)
This chart breaks down Jagsonpal Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.07 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jagsonpal Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jagsonpal Pharmaceuticals Limited (2006–2025)
The table below shows the annual total liabilities of Jagsonpal Pharmaceuticals Limited from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹383.10 Million | +29.09% |
| 2024-03-31 | ₹296.76 Million | -17.70% |
| 2023-03-31 | ₹360.56 Million | -4.10% |
| 2022-03-31 | ₹375.99 Million | -11.06% |
| 2021-03-31 | ₹422.73 Million | +17.68% |
| 2020-03-31 | ₹359.21 Million | +14.72% |
| 2019-03-31 | ₹313.11 Million | -1.44% |
| 2018-03-31 | ₹317.68 Million | -2.84% |
| 2017-03-31 | ₹326.97 Million | -46.32% |
| 2016-03-31 | ₹609.17 Million | +3.61% |
| 2015-03-31 | ₹587.94 Million | +1.95% |
| 2014-03-31 | ₹576.68 Million | +5.56% |
| 2013-03-31 | ₹546.30 Million | -5.21% |
| 2012-03-31 | ₹576.30 Million | +31.56% |
| 2011-03-31 | ₹438.04 Million | +22.81% |
| 2010-03-31 | ₹356.69 Million | -16.29% |
| 2009-03-31 | ₹426.09 Million | -22.84% |
| 2008-03-31 | ₹552.21 Million | -26.36% |
| 2007-03-31 | ₹749.83 Million | +5.14% |
| 2006-03-31 | ₹713.18 Million | -- |